Zacks' Focus List, a portfolio leveraging earnings estimate revisions and the proprietary Zacks Rank, has delivered substantial outperformance, with a cumulative return of 2,519.23% since 1996 compared to the S&P 500's 854.95%. HCA Healthcare exemplifies this strategy, having appreciated 216.44% since its January 2019 inclusion on the list. Despite its current Zacks #3 (Hold) rating, HCA remains notable due to recent upward revisions from 10 analysts for FY2025 earnings, an increased consensus estimate of $26.11, and projected current fiscal year earnings growth of 18.9%.
HCA Healthcare (HCA) is highlighted for its significant long-term stock appreciation, having increased 216.44% to $390.46 since being added to the Zacks Focus List in January 2019. The company's forward-looking fundamentals appear robust, underpinned by a projected earnings growth of 18.9% for the current fiscal year and a historical average earnings surprise of 7%. Analyst sentiment for fiscal 2025 is constructive, evidenced by 10 upward earnings estimate revisions over the last 60 days, which has lifted the Zacks Consensus Estimate to $26.11. This positive outlook on future earnings, however, is contrasted by the stock's current Zacks #3 (Hold) rating, which may signal that near-term price momentum could be moderating despite the strong underlying growth narrative.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment